WEBINAR | Inflammation as a Clinical Endpoint in CKM: Are We There Yet?
Inflammation is increasingly being explored as a potential link across cardiovascular, kidney and metabolic (CKM) disease. But as interest grows, an important question remains: Is the evidence strong enough for inflammation to become a meaningful clinical endpoint in CKM?
In this webinar, experts from Syneos Health Anup Sabharwal, Jim Snyder and Tristan Baldwinson examine the evidence supporting inflammation's role in CKM development and discuss the challenges that must be addressed before it can be considered a meaningful clinical endpoint.
They explored the questions: Is inflammation the smoke or the fire in CKM disease? Is it primarily a biomarker of risk or a treatment target for selected patients? Should inflammation be viewed as a shared treatment target across cardiovascular, kidney, metabolic and liver disease? Or is it still too early to distinguish a marker from a treatment target? These questions are explored through a robust discussion grounded in biological theory and clinical trial evidence.
Whether you're evaluating inflammation as a therapeutic target, biomarker or future endpoint, this recording provides practical insight into where the science stands today and where it may be headed.
Watch the webinar to see the evidence and discussion firsthand.
Related Content
Looking for exclusive insight?
